Alle Storys
Folgen
Keine Story von Marseille-Kliniken AG mehr verpassen.

Marseille-Kliniken AG

EANS-News: Annual general meeting of Marseille-Kliniken AG resolves moderate dividend

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Subtitle: - Payout of a dividend of EUR 0.11 per share resolved
- Dividend payout ratio of 24 % does not negatively affect the Groups further
recovery
- Conversion to registered shares increases transparency


Annual & Special Corporate Meetings/Annual & Special Corporate Meetings/Dividend
payout approved

Hamburg (euro adhoc) - 03 December 2012 - The annual general meeting of
Marseille-Kliniken AG held today at it's headquarter in Hamburg approved an
application which was introduced by major shareholder Ulrich Marseille about the
payout of a dividend of EUR 0.11 per share. All remaining applications
introduced by the company's administration were approved with high majority
rates. The attending shareholders represented approx. 68 percent of the share
capital.

By the decision for the payout of a dividend with a ratio of 24 percent of the
net income, the shareholders on the one hand participate in the near term from
the company's positive development in the last business year 2011/2012. On the
other hand the disposition of most of the profit within the group raises the
potential for further improving the financial strength. The group managed to
more than double its earnings in the last business year as well as in the first
quarter of the new business year 2012/2013. This makes the simultaneous payout
of the dividend and the improvement of the financial power possible.

Upon administration's application moreover a separate formal approval of the
directors who had been in place during last business year 2011/2012 took place.
The majority of the participating shareholders decided not to relieve former
directors Dr. Thomas Klaue and Stefan Herzberg. In contrast current chairman
Michael Thanheiser such as former CEO Ulrich Marseille were granted relief from
the shareholders.

Moreover resolved was a conversion from bearer to registered shares. This
resolution reflects the strategic reorientation and the internal reorganisation
which have been carried out by the company since business year 2010/2011. The
conversion to registered shares improves the possibilities for communication
with shareholders and thus strengthens transparency.

Michael Thanheiser, chairman of Marseille-Kliniken AG, comments the AGM's
resolutions as follows: "Our shareholders have built the basis for a more
efficient communication with the company by their decision for the conversion to
registered shares. We can of course also understand the shareholders' desire for
a payout of a dividend, although we had originally planned to carry forward the
entire profit to new account. Now we return to a shareholder friendly dividend
policy a little earlier, which is however realizable for us due to the earnings
and cash flow development. I therefore consider this resolution of the AGM as a
good decision." Dieter Wopen, who is newly appointed as chairman since 15
November 2012, supplements: "The opportunity of introducing me to the
shareholders at the AGM was a good start for my future activity for
Marseille-Kliniken AG. I am looking forward for a successful co-operation with
Michael Thanheiser and the complete management team."


Further inquiry note:
Hillermann Consulting
Jan Pahl
Investor Relations for Marseille-Kliniken AG
Poststraße 14-16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 3202791-0
www.marseille-kliniken.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Marseille-Kliniken AG
             Alte Jakobstraße 79/80
             D-10179 Berlin
phone:       +49 (0)30 246 32-400
FAX:         +49 (0)30 246 32-401
mail:         info@marseille-kliniken.de
WWW:         http://www.marseille-kliniken.de
sector:      Pharmaceuticals
ISIN:        DE0007783003
indexes:     CDAX, Classic All Share, Prime All Share
stockmarkets: free trade: Berlin, Düsseldorf, Stuttgart, regulated dealing:
             Hamburg, regulated dealing/prime standard: Frankfurt 
language:   English

Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell

Weitere Storys: Marseille-Kliniken AG
Weitere Storys: Marseille-Kliniken AG